Pharmaceutical Firm Introduces Dual-Action Therapy for Metabolic Conditions
New Tirzepatide Formulation Aims to Broaden Access Across India for Diabetes and Obesity Management
Cipla Limited has unveiled a new medication, known as Yurpeak, which contains the active pharmaceutical ingredient tirzepatide. This injectable treatment is administered once every week and is indicated for managing adult patients afflicted by type 2 diabetes or chronic obesity.
The introduction is viewed as a significant development in the domestic effort to combat the growing prevalence of metabolic disorders in India.
Yurpeak is the second available iteration of tirzepatide in the Indian market. Its distribution is facilitated through a newly established partnership between Cipla and Eli Lilly and Company. The collaboration is strategically designed to ensure the medication’s availability extends past major metropolitan areas and into smaller and semi-urban localities, thereby addressing the nation’s substantial burden of high body mass index and diabetes.
Tirzepatide functions by activating both the GIP and GLP-1 receptors. This dual mechanism assists in regulating glucose levels and facilitating weight reduction. It is prescribed as a supplemental treatment alongside changes in diet and physical activity for individuals diagnosed with type 2 diabetes or those with chronic obesity (defined as a Body Mass Index of 30 or higher, or a BMI of 27 or higher with associated weight-related health issues).
The product is supplied via prescription in KwikPen pre-filled injectors, offering six distinct dosage options, ranging from 2.5 milligrams to 15 milligrams, allowing for personalized patient care. Furthermore, Cipla commits to providing educational materials and programs for patients, focusing on accurate self-administration, correct dosage procedures, and the necessity of informed discussions with medical practitioners.
